Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.76
-4.3%
$1.70
$0.55
$2.17
$120.17M0.95355,600 shs199,808 shs
DRMAW
Dermata Therapeutics
$0.01
$0.01
$0.01
$0.04
N/AN/A10,236 shs1,000 shs
High Tide Inc. stock logo
HITI
High Tide
$2.02
-5.6%
$1.97
$1.14
$2.85
$160.25M0.54526,882 shs909,385 shs
Procaps Group S.A. stock logo
PROC
Procaps Group
$2.75
$3.01
$1.95
$4.95
N/A0.1320,385 shs686 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-4.35%+0.57%+20.55%+58.56%+183.87%
DRMAW
Dermata Therapeutics
0.00%0.00%-16.36%-38.67%-48.89%
High Tide Inc. stock logo
HITI
High Tide
-5.61%-9.82%+7.45%+6.88%+60.32%
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00%+2.61%-8.33%-33.09%-40.35%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.2305 of 5 stars
3.53.00.00.03.70.00.6
DRMAW
Dermata Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
High Tide Inc. stock logo
HITI
High Tide
2.428 of 5 stars
3.54.00.00.03.70.80.0
Procaps Group S.A. stock logo
PROC
Procaps Group
2.8354 of 5 stars
3.03.00.00.02.60.82.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
3.00
Buy$6.00240.91% Upside
DRMAW
Dermata Therapeutics
N/AN/AN/AN/A
High Tide Inc. stock logo
HITI
High Tide
3.00
Buy$4.50122.77% Upside
Procaps Group S.A. stock logo
PROC
Procaps Group
2.00
Hold$4.5063.64% Upside

Current Analyst Ratings

Latest PROC, ADVT, CRDL, DRMAW, and HITI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
3/25/2024
High Tide Inc. stock logo
HITI
High Tide
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.50
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$60K2,002.88N/AN/A$0.32 per share5.50
DRMAW
Dermata Therapeutics
N/AN/AN/AN/AN/AN/A
High Tide Inc. stock logo
HITI
High Tide
$361.57M0.44$0.24 per share8.33$1.32 per share1.53
Procaps Group S.A. stock logo
PROC
Procaps Group
$409.92MN/A$0.53 per share5.15($0.02) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$20.84M-$0.33N/AN/AN/AN/A-76.18%-62.52%5/20/2024 (Estimated)
DRMAW
Dermata Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
High Tide Inc. stock logo
HITI
High Tide
-$29.14M-$0.33N/A14.43N/A-7.46%-2.03%-1.23%6/12/2024 (Estimated)
Procaps Group S.A. stock logo
PROC
Procaps Group
$42.54M$0.525.2916.18N/A12.61%283.06%11.04%6/3/2024 (Estimated)

Latest PROC, ADVT, CRDL, DRMAW, and HITI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/A-$0.09-$0.09-$0.09N/AN/A
3/18/2024Q1 2024
High Tide Inc. stock logo
HITI
High Tide
-$0.03-$0.01+$0.02N/A$94.43 million$94.76 million  
1/29/2024Q4 2023
High Tide Inc. stock logo
HITI
High Tide
-$0.03$0.02+$0.05$0.33$92.60 million$93.59 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
DRMAW
Dermata Therapeutics
N/AN/AN/AN/AN/A
High Tide Inc. stock logo
HITI
High Tide
N/AN/AN/AN/AN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.01
4.36
4.36
DRMAW
Dermata Therapeutics
N/AN/AN/A
High Tide Inc. stock logo
HITI
High Tide
0.20
1.13
0.69
Procaps Group S.A. stock logo
PROC
Procaps Group
5.74
1.47
0.99

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
DRMAW
Dermata Therapeutics
N/A
High Tide Inc. stock logo
HITI
High Tide
4.52%
Procaps Group S.A. stock logo
PROC
Procaps Group
N/A

Insider Ownership

CompanyInsider Ownership
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
5.25%
DRMAW
Dermata Therapeutics
N/A
High Tide Inc. stock logo
HITI
High Tide
12.44%
Procaps Group S.A. stock logo
PROC
Procaps Group
19.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/A68.28 million64.70 millionNot Optionable
DRMAW
Dermata Therapeutics
8N/AN/ANot Optionable
High Tide Inc. stock logo
HITI
High Tide
1,55079.33 million69.47 millionOptionable
Procaps Group S.A. stock logo
PROC
Procaps Group
5,500N/AN/ANot Optionable

PROC, ADVT, CRDL, DRMAW, and HITI Headlines

SourceHeadline
Procaps Group (NASDAQ:PROC) Trading Down 3%Procaps Group (NASDAQ:PROC) Trading Down 3%
americanbankingnews.com - April 19 at 2:59 AM
Global Gummy Market Size To Worth USD 66.56 Billion By 2033 | CAGR of 11.32%Global Gummy Market Size To Worth USD 66.56 Billion By 2033 | CAGR of 11.32%
finance.yahoo.com - March 29 at 11:16 AM
Rising Demand for Natural Products Fuels Growth of Vegetarian Softgel Capsules Market | Market.usRising Demand for Natural Products Fuels Growth of Vegetarian Softgel Capsules Market | Market.us
pharmiweb.com - March 15 at 6:23 PM
Procaps explores strategic alternatives to boost shareholder valueProcaps explores strategic alternatives to boost shareholder value
investing.com - March 6 at 5:48 PM
Procaps Announces Formation of Strategic Committee to Explore Value Creation AlternativesProcaps Announces Formation of Strategic Committee to Explore Value Creation Alternatives
finance.yahoo.com - March 4 at 8:37 AM
Procaps Issues Shareholder Letter from New CEOProcaps Issues Shareholder Letter from New CEO
finance.yahoo.com - February 5 at 1:39 PM
Does This Valuation Of Procaps Group S.A. (NASDAQ:PROC) Imply Investors Are Overpaying?Does This Valuation Of Procaps Group S.A. (NASDAQ:PROC) Imply Investors Are Overpaying?
finance.yahoo.com - February 1 at 8:19 AM
Procaps Group S.A. (PROCW)Procaps Group S.A. (PROCW)
ca.finance.yahoo.com - January 21 at 3:59 PM
PROC Procaps Group S.A.PROC Procaps Group S.A.
seekingalpha.com - January 21 at 3:59 PM
Procaps Group – Notice to ShareholdersProcaps Group – Notice to Shareholders
finance.yahoo.com - January 16 at 12:40 PM
Pharma Company Procaps Beats On Q3 But Lowers FY23 Guidance: Heres WhyPharma Company Procaps Beats On Q3 But Lowers FY23 Guidance: Here's Why
msn.com - December 27 at 10:22 AM
Procaps Group reports Q3 results; updates FY23 outlookProcaps Group reports Q3 results; updates FY23 outlook
msn.com - December 27 at 5:22 AM
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top EstimatesProcaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
msn.com - December 26 at 8:22 PM
Procaps Group Reports Third Quarter 2023 ResultsProcaps Group Reports Third Quarter 2023 Results
finance.yahoo.com - December 26 at 8:22 PM
Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin AmericaProcaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America
finance.yahoo.com - November 29 at 7:26 PM
Procaps Group Names Vieira to Succeed Minski as CEOProcaps Group Names Vieira to Succeed Minski as CEO
marketwatch.com - November 22 at 1:41 PM
Procaps Group Appoints Jose Antonio Vieira To Succeed Ruben Minski As CEOProcaps Group Appoints Jose Antonio Vieira To Succeed Ruben Minski As CEO
markets.businessinsider.com - November 22 at 1:41 PM
Procaps Group says CEO Minski to step down from the roleProcaps Group says CEO Minski to step down from the role
msn.com - November 22 at 1:41 PM
Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024
finance.yahoo.com - November 22 at 1:41 PM
Procaps Group Update on Third Quarter ResultsProcaps Group Update on Third Quarter Results
finance.yahoo.com - November 14 at 6:59 PM
Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023
finance.yahoo.com - November 10 at 2:19 PM
Procaps Group S.A. (NASDAQ:PROC) insiders have significant skin in the game with 60% ownershipProcaps Group S.A. (NASDAQ:PROC) insiders have significant skin in the game with 60% ownership
finance.yahoo.com - November 5 at 1:48 PM
Procaps Group S.A. WtProcaps Group S.A. Wt
barrons.com - October 29 at 7:00 AM
Procaps Appoints Sandra Sánchez y Oldenhage to Board of DirectorsProcaps Appoints Sandra Sánchez y Oldenhage to Board of Directors
finance.yahoo.com - October 23 at 6:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Cardiol Therapeutics logo

Cardiol Therapeutics

NASDAQ:CRDL
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Dermata Therapeutics

NASDAQ:DRMAW
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
High Tide logo

High Tide

NASDAQ:HITI
High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Retail and Wholesale segments. It operates licensed retail cannabis stores; and provides data analytics services. In addition, the company manufactures and distributes consumption accessories. Further, it sells its products through online sales via e-commerce platform. The company offers its products under the Daily High Club, DankStop, FABCBD, GC, Nuleaf, Smoke Cartel, and Blessed CBD brands. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. High Tide Inc. was founded in 2009 and is headquartered in Calgary, Canada.
Procaps Group logo

Procaps Group

NASDAQ:PROC
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.